Iovance Biotherapeutics Announces Clinical Programs Update Read more about Iovance Biotherapeutics Announces Clinical Programs Update
Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma Read more about Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma
Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel Read more about Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel
Iovance Biotherapeutics Announces April Scientific and Investor Presentations Read more about Iovance Biotherapeutics Announces April Scientific and Investor Presentations
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March Read more about Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March
Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer Read more about Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update Read more about Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019 Read more about Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences
Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Read more about Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference